Clinical trials: Pancreatic Ca
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
Background: Pancreatic cancer is difficult to treat because by the time most cases are diagnosed, the tumors are too large to be removed surgically.
- Trial name
- NCT01294358
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Pancreatic Ductal
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis.
- Trial name
- PF-BARNA (NCT05489458)
- Testing
- Resection, No Resection
- Volunteers
- 100 people
- Sponsor
- BUSQUETS, JULI
Resectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the…
- Trial name
- RADAR-PANC (NCT04875325)
- Testing
- Standardized surveillance
- Where
- 11 sites in Netherlands, United Kingdom
- Volunteers
- 306 people
- Sponsor
- UMC Utrecht
Pancreatic Neoplasms
EUS-guided RFA for Pancreatic Neoplasms
Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms.
- Trial name
- NCT03218345
- Testing
- EUS-guided RFA
- Where
- Hong Kong
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Pancreatic Cancer, Adult, Perineural Invasion
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
Pancreatic cancer has an incidence of 1,401,450 new cases diagnosed annually worldwide and is the third leading cause of cancer-related death in Spain.
- Conditions
- Pancreatic Cancer, Adult, Perineural Invasion, Neutrophil-to-Lymphocyte Ratio, CA 19.9
- Trial name
- NCT06747481
- Where
- Spain
- Volunteers
- 323 people
- Sponsor
- University of Las Palmas de Gran Canaria